Contact Us
Find A Doctor

Primary Open Angle Glaucoma Treatment

Study Title

A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Enrollment Status

Completed

Purpose

The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.

Eligibility

Ages Eligible for Study: 18 Years to 75 Years

Genders Eligible for Study: Both

Inclusion Criteria

  • Subjects with the diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma (POAG).
  • Aged 18 to 75 years.
  • Mean intraocular pressure (IOP) of ≥24 and ≤34 mm Hg.

 

Contact Us

Dr. Paul Sidoti, Principal Investigator

Katy Tai, Research ManagerTel: (212) 979-4251

Address310 E. 14th StreetNew York, NY 10003

View all locations